Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma

RecruitingOBSERVATIONAL

Enrollment

2,000

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Hepatocellular Carcinoma

Interventions

DRUG

Conversion or neoadjuvant therapy.

Patients with hepatocellular carcinoma received conversion or neoadjuvant therapy.

Trial Locations (1)

RECRUITING

Jian-Hong Zhong, Nanning

All Listed Sponsors

lead

Guangxi Medical University

OTHER